Brief: Histopathology And Tumor Biomarker Analysis Confirm Cel-Sci's Multikine Significantly Prolonged Overall Survival In Head & Neck Cancer—Phase 3 Data Presented At ESTRO 2023
15/05/2023 14:17
May 15 (Reuters) - CEL-SCI Corp CVM.A :
* HISTOPATHOLOGY AND TUMOR BIOMARKER ANALYSIS CONFIRM
CEL-SCI’S
MULTIKINE SIGNIFICANTLY PROLONGED OVERALL SURVIVAL IN HEAD &
NECK CANCER—PHASE 3 DATA PRESENTED AT ESTRO 2023
Source text for Eikon: ID:nBw8G4WPza
Further company coverage: CVM.A
((Reuters.Brief@thomsonreuters.com;))
Recent news on CEL-SCI
See all newsBrief: CEL-SCI Announces Closing Of Offering
Brief: Cel-Sci Corp Files For Offering Of 6 Million Shares Of Common Stock- SEC Filing
Brief: Cel-Sci Corporation Announces Pricing Of Public Offering
Brief: CEL-SCI Enters Strategic Agreement With Amarox For The Registration, Commercialization, And Distribution Of Multikine In Saudi Arabia
Drug developer CEL-SCI dives on deep-discounted equity raise